NASDAQ:FENC

Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis

$9.24
-0.14 (-1.49%)
(As of 04/23/2024 ET)
Today's Range
$9.05
$9.61
50-Day Range
$8.82
$11.12
52-Week Range
$6.30
$11.92
Volume
288,706 shs
Average Volume
121,963 shs
Market Capitalization
$250.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33

Fennec Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
87.6% Upside
$17.33 Price Target
Short Interest
Bearish
9.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.15mentions of Fennec Pharmaceuticals in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$1.96 M Sold Last Quarter
Proj. Earnings Growth
536.36%
From $0.11 to $0.70 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.41 out of 5 stars

Medical Sector

474th out of 909 stocks

Biological Products, Except Diagnostic Industry

74th out of 156 stocks

FENC stock logo

About Fennec Pharmaceuticals Stock (NASDAQ:FENC)

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

FENC Stock Price History

FENC Stock News Headlines

How to camouflage a factory of 53,000 workers
"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."
How to camouflage a factory of 53,000 workers
"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Short Interest Update
Q4 2023 Fennec Pharmaceuticals Inc Earnings Call
FENC Apr 2024 12.500 call
See More Headlines
Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/21/2024
Today
4/24/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FENC
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.33
High Stock Price Target
$18.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+87.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-16,050,000.00
Pretax Margin
-75.52%

Debt

Sales & Book Value

Annual Sales
$21.25 million
Book Value
($0.43) per share

Miscellaneous

Free Float
24,051,000
Market Cap
$250.40 million
Optionable
Optionable
Beta
0.38
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

FENC Stock Analysis - Frequently Asked Questions

Should I buy or sell Fennec Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FENC shares.
View FENC analyst ratings
or view top-rated stocks.

What is Fennec Pharmaceuticals' stock price target for 2024?

3 analysts have issued 12-month target prices for Fennec Pharmaceuticals' shares. Their FENC share price targets range from $16.00 to $18.00. On average, they expect the company's share price to reach $17.33 in the next twelve months. This suggests a possible upside of 87.6% from the stock's current price.
View analysts price targets for FENC
or view top-rated stocks among Wall Street analysts.

How have FENC shares performed in 2024?

Fennec Pharmaceuticals' stock was trading at $11.22 at the beginning of the year. Since then, FENC stock has decreased by 17.6% and is now trading at $9.24.
View the best growth stocks for 2024 here
.

Are investors shorting Fennec Pharmaceuticals?

Fennec Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,810,000 shares, an increase of 7.1% from the March 15th total of 1,690,000 shares. Based on an average daily trading volume, of 110,600 shares, the short-interest ratio is currently 16.4 days. Approximately 9.1% of the shares of the company are short sold.
View Fennec Pharmaceuticals' Short Interest
.

When is Fennec Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our FENC earnings forecast
.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) issued its quarterly earnings data on Thursday, March, 21st. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by $0.12. The business had revenue of $9.74 million for the quarter, compared to the consensus estimate of $9.47 million.

What guidance has Fennec Pharmaceuticals issued on next quarter's earnings?

Fennec Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $20.7 million-$21.2 million, compared to the consensus revenue estimate of $19.6 million.

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FENC) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners